Top 10 GLP-1 Weight Loss Medications Transforming Health in 2026

Wegovy (semaglutide 2.4 mg) is the only weight-loss drug with a proven cardiovascular benefit, reducing major adverse cardiac events by 20% in the SELECT trial of 17,604 non-diabetic adults. As a pure GLP-1 receptor agonist, it achieves 14.9% average weight loss at 68 weeks in the STEP 1 trial — roughly 34 pounds — but trails #1 Zepbound's 20.9% efficacy. However, Wegovy's landmark cardiovascular risk-reduction indication, approved in March 2024, provides unmatched heart protection. Weekly doses escalate over 16-20 weeks to minimize side effects, and monthly list price is approximately $1,349, with savings programs reducing costs to $25 per month for eligible patients.

Retatrutide, Eli Lilly's investigational triple GLP-1/GIP/glucagon receptor agonist, achieved a 30.3% average weight loss in the TRIUMPH-1 Phase 3 trial — the highest ever recorded in a randomized obesity trial. This outperforms #1 Zepbound's 20.9% and #2 Wegovy's 14.9% by engaging glucagon receptors to boost thermogenesis and fat oxidation. At 12 mg weekly over 96 weeks, participants lost approximately 70-71 pounds, with additional benefits including a 75.8% reduction in osteoarthritis pain and a 72% reversal rate of prediabetes. An NDA filing is expected in late 2026, with approval anticipated in 2027; no list price or commercial name is yet available.

CagriSema, a fixed-dose combination of cagrilintide 2.4 mg (an amylin analogue) and semaglutide 2.4 mg, achieved 22.7% average weight loss in the REDEFINE 1 Phase 3 trial — exceeding #2 Wegovy's 14.9% by adding amylin receptor activation for synergistic appetite suppression. Among completers, 91.9% lost at least 5% of body weight versus 31.5% with placebo, with one-third losing 25% or more. An NDA was submitted to the FDA on December 18, 2025, positioning it as the most advanced next-generation obesity therapy. Approval is expected by late 2026 or early 2027; no list price or commercial brand is yet available.

The oral Wegovy pill (oral semaglutide 25 mg) is the first FDA-approved oral GLP-1 specifically for weight management, eliminating the need for self-injection while matching injectable Wegovy's efficacy. Approved on December 22, 2025, and launched in January 2026, the OASIS 4 Phase 3 trial showed adherent participants lost an average of 16.6% body weight, with one-third achieving at least 20% weight loss compared to under 3% for placebo. Its cardiovascular risk-reduction indication adds clinical depth. However, the strict fasting requirement—no food for 6 hours, only 4 oz of water, and a 30-minute post-ingestion wait—creates adherence challenges. This dosing protocol is stricter than Foundayo (orforglipron), which can be taken at any time without food restrictions. At a list price of $499 per month with savings programs, it is a potent but logistically demanding option.

Foundayo (orforglipron) by Eli Lilly is the first FDA-approved non-peptide small-molecule oral GLP-1, approved on April 1, 2026, offering flexible intake with or without food—a critical real-world advantage over oral semaglutide (Wegovy oral), which requires strict fasting. The Phase 3 ATTAIN trial demonstrated a 12.4% average weight loss at 36 mg daily over 72 weeks, with 60% of participants achieving at least 10% reduction. While 12.4% is lower than oral semaglutide's 16.6%, the no-food-restriction dosing likely improves long-term adherence. A standout feature is pricing: $149 per month for self-pay patients, which is dramatically lower than every other GLP-1, with commercially insured patients paying as low as $25 via savings card. Cardiovascular outcomes trials are ongoing, and this affordability could expand GLP-1 access widely.

Ozempic (semaglutide up to 2 mg weekly) holds the most expansive FDA indications of any GLP-1, including glycemic control in type 2 diabetes, reduction of major adverse cardiovascular events, and, as of January 28, 2025, reduction of worsening kidney disease and cardiovascular death in type 2 diabetes patients with CKD. The Phase 3b FLOW trial demonstrated a 24% relative risk reduction in a composite of kidney disease worsening, end-stage kidney disease, and cardiovascular death, plus a 29% relative risk reduction in CV death—making it the only GLP-1 RA with a kidney protection indication. While not formally approved for weight management, it induces 5-10% weight reduction at 1-2 mg doses. At a monthly list price of $900-$1,000 without insurance, it provides a lower-cost entry into the GLP-1 class for millions compared to Wegovy, with better diabetes coverage.

MariTide (maridebart cafraglutide) by Amgen is a novel investigational antibody-peptide conjugate that uniquely agonizes GLP-1 while antagonizing GIP—the inverse mechanism of tirzepatide, offering a distinct metabolic pathway. Phase 2 data in the New England Journal of Medicine showed approximately 20% weight loss in non-diabetic adults after 52 weeks and about 17% in those with type 2 diabetes, with HbA1c reductions of up to 1.6 percentage points. Crucially, MariTide demonstrated sustained weight loss for up to 52 weeks after treatment stopped, a durability advantage over peptide-based GLP-1s like Ozempic (semaglutide injection), whose effects wane quickly. Its most disruptive feature is once-monthly dosing, potentially once-quarterly, versus weekly injections for all current GLP-1s. However, Phase 2 results fell short of analyst expectations, and Phase 3 trials are ongoing through 2026-2027.

Rybelsus (Oral Semaglutide 14 mg) stands alone as the only oral GLP-1 approved for both glycemic control and cardiovascular risk reduction in type 2 diabetes, a dual indication that expands its therapeutic reach since its September 2019 debut as the first oral GLP-1. By leveraging Novo Nordisk's SNAC absorption enhancer, it overcomes gastric degradation to deliver systemic absorption, and the SOUL trial (n=9,650) confirmed a 14% relative reduction in major adverse cardiovascular events versus placebo over 4 years, earning FDA approval for cardiovascular risk reduction in October 2025. At the 14 mg dose, PIONEER trials showed approximately 4-5 kg weight loss, which underperforms #1 Wegovy (semaglutide) by nearly 60%. Rybelsus requires strict fasting: an empty stomach, no more than 120 mL of water, and 30 minutes without food or medications. With a monthly list price from $900 to $1,000, it is more affordable than weight-loss-only GLP-1s like #2 Saxenda's $1,349 list price. For T2D patients with established cardiovascular disease, Rybelsus remains the definitive oral option, even as oral Wegovy (25 mg) enters the market.

Saxenda (liraglutide 3 mg) pioneered chronic weight management as the first GLP-1 approved for that indication in December 2014, achieving an average 8-10% body weight loss in the SCALE trials over 56 weeks—outperforming orlistat's 3-5% average by 167%. The SCALE Obesity and Prediabetes trial reported 5.8 kg weight loss versus 1.6 kg with placebo. Once-daily injections leverage an 18-24 hour half-life, and Saxenda uniquely holds approval for adolescents aged 12-17. The key development in 2025-2026 is FDA approval of generic liraglutide, reducing monthly costs to $230-$500 compared to Saxenda's $1,349 list price; Teva's program can drop it to $20 per prescription for commercially insured patients. While its efficacy trails #1 Wegovy and #2 Zepbound, generic pricing and a decade-plus safety record make Saxenda a cost-effective bridge therapy for patients who face affordability obstacles with higher-rated options.